{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:56:48Z","timestamp":1792238208162,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jns.2021.120089","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:47:15Z","timestamp":1639655235000},"page":"120089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review"],"prefix":"10.1016","volume":"432","author":[{"given":"Erum","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish K.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elkhooly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ebbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitiz","family":"Sriwastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.120089_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","article-title":"Mechanisms of immune evasion by tumors","volume":"90","author":"Drake","year":"2006","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2021.120089_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.jns.2021.120089_bb0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"issue":"7","key":"10.1016\/j.jns.2021.120089_bb0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.jns.2021.120089_bb0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5256","key":"10.1016\/j.jns.2021.120089_bb0035","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"issue":"19","key":"10.1016\/j.jns.2021.120089_bb0040","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.jns.2021.120089_bb0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.120089_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined NIVOLUMAB AND IPILIMUMAB OR MONOTHERAPY IN UNTREATED MELANOMA","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.jns.2021.120089_bb0060","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.jns.2021.120089_bb0070","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.jns.2021.120089_bb0075","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.jns.2021.120089_bb0080","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jns.2021.120089_bb0085","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jns.2021.120089_bb0090","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ."},{"issue":"6","key":"10.1016\/j.jns.2021.120089_bb0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jns.2021.120089_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.jns.2021.120089_bb0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2021.120089_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.jns.2021.120089_bb0115","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.120089_bb0120","doi-asserted-by":"crossref","first-page":"9800488","DOI":"10.1155\/2021\/9800488","article-title":"Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"152","key":"10.1016\/j.jns.2021.120089_bb0125","first-page":"107","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients","volume":"28","author":"Patel","year":"2019","journal-title":"Discov. Med."},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","article-title":"Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"268","author":"Okada","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.120089_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26070","article-title":"Neuromuscular complications of immune checkpoint inhibitor therapy","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2021.120089_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2018.06.024","article-title":"New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent","volume":"392","author":"Desai","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series","volume":"76","author":"Strohbehn","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"10.1016\/j.jns.2021.120089_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230848","article-title":"Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab","volume":"12","author":"Pierrard","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"11\u201312 Pt 2","key":"10.1016\/j.jns.2021.120089_bb0155","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.lpm.2018.10.009","article-title":"Neuromuscular complications of immune checkpoint inhibitors","volume":"47","author":"Psimaras","year":"2018","journal-title":"Presse Med."},{"issue":"1\u20132","key":"10.1016\/j.jns.2021.120089_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-associated acute demyelinating encephalitis: a case report and literature review","volume":"17","author":"Zafar","year":"2019","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.jns.2021.120089_bb0165","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","author":"Sun","year":"2020","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2021.120089_bb0170","first-page":"8845063","article-title":"Posterior reversible encephalopathy syndrome (PRES) and drug-induced hypersensitivity syndrome (DIHS) following immunotherapy and BRAF\/MEK inhibition with continued response in metastatic Melanoma","volume":"2021","author":"Sabile","year":"2021","journal-title":"Case Rep. Oncol. Med."},{"issue":"16","key":"10.1016\/j.jns.2021.120089_bb0175","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jns.2021.120089_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jns.2021.120089_bb0185","series-title":"The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Review: Checklists for Case Reports","author":"Joanna","year":"2019"},{"issue":"11","key":"10.1016\/j.jns.2021.120089_bb0190","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jns.2021.120089_bb0195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jns.2021.120089_bb0200","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","author":"Morelli","year":"2021","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jns.2021.120089_bb0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials","volume":"25","author":"Bruna","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2021.120089_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0220","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2021.120089_bb0225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jns.2021.120089_bb0235","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0240","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2021.120089_bb0245","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barr\u00e9 syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2021.120089_bb0250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","article-title":"Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barr\u00e9 syndrome","volume":"390","author":"Nukui","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2021.120089_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barr\u00e9-like syndrome during pembrolizumab treatment","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0260","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/mus.25663","article-title":"Facial diplegia after pembrolizumab treatment","volume":"56","author":"Yost","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2021.120089_bb0265","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0270","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced Guillain-Barr\u00e9 syndrome in a patient with metastatic Melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"10","key":"10.1016\/j.jns.2021.120089_bb0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jns.2021.120089_bb0280","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J. Immunother. Cancer."},{"issue":"3","key":"10.1016\/j.jns.2021.120089_bb0285","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.jns.2021.120089_bb0290","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jns.2021.120089_bb0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2021.120089_bb0300","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.jns.2021.120089_bb0305","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"50","key":"10.1016\/j.jns.2021.120089_bb0310","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2102791X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2102791X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:21Z","timestamp":1758383961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2102791X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":62,"alternative-id":["S0022510X2102791X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120089","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120089"}}